A Phase 1, Double‐Blind, Placebo‐Controlled Trial of Sevasemten ( EDG ‐5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy
Muscle & Nerve · 2025-09 · 72 (3) · 399-407
DOI: 10.1002/mus.28444 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Muscle & Nerve, online erschienen am 02.06.2025. Verfasst von Joanne Donovan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Edgewise Therapeutics, Inc., Boulder, Colorado, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Muscle, Skeletal, Muscle Contraction. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Edgewise Therapeutics Inc.
Abstract (Originalsprache)
Introduction/Aims Sevasemten (EDG‐5506) is an orally administered, investigational small molecule that selectively modulates fast muscle fiber contraction by inhibiting fast myosin ATPase. This study assessed the safety, tolerability, and pharmacokinetics (PK)/pharmacodynamics (PD) of sevasemten in healthy adult volunteers (HVs) and adults with Becker muscular dystrophy (BMD).
Methods
This randomized, double‐blind, placebo‐controlled phase 1 study was conducted at a single site. Eligible participants were 18–55 years of age with a body mass index < 30 kg/m 2 ; adults with BMD were required to have a confirmed diagnosis based on documentation of pathogenic variant(s) in the dystrophin gene and a BMD phenotype. Participants were randomized 3:1 to receive sevasemten or placebo for up to 14 days. Endpoints included adverse events (AEs), sevasemten PK and muscle concentration, and changes in biomarkers of muscle injury.
Results
The study enrolled 97 HVs in 7 single‐dose cohorts ( N = 57) and 5 multiple‐dose cohorts ( N = 40). Seven adults with BMD were enrolled in a multiple‐dose cohort. There were no serious AEs or AEs leading to trial discontinuation; the most common AEs were dizziness and somnolence. For adults with BMD, serum biomarkers of muscle injury trended down progressively with sevasemten treatment (average maximal reductions of 70% for creatine kinase, 98% for fast skeletal muscle troponin I, and 45% for myoglobin). Plasma proteomic analysis identified a signature of 125 elevated proteins characteristic of BMD that was reversibly lowered with sevasemten treatment.
Discussion
Sevasemten was generally well tolerated. Preliminary observations of decreases in biomarkers of muscle damage in adults with BMD support further clinical development. Trial Registration: NCT04585464
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Edgewise Therapeutics, Inc., Boulder, Colorado, USA.
ORCID-Profile: Alan J Russell
Förderung
- Edgewise Therapeutics Inc
Zitieren
APA
Donovan, J., Silverman, J. A., Barthel, B., DuVall, M., Madden, M., MacDougall, J., Kilburn, N. R., Bronson, A., Evanchik, M., Gordon, G., Koch, K., & Russell, A. J. (2025). A Phase 1, Double‐Blind, Placebo‐Controlled Trial of Sevasemten ( EDG ‐5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy. Muscle & Nerve, 72(3), 399-407. https://doi.org/10.1002/mus.28444
Vancouver
Donovan J, Silverman JA, Barthel B, DuVall M, Madden M, MacDougall J, et al. A Phase 1, Double‐Blind, Placebo‐Controlled Trial of Sevasemten ( EDG ‐5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy. Muscle & Nerve. 2025;72(3):399-407. doi:10.1002/mus.28444
BibTeX
@article{Donovan2025,
author = {Donovan, Joanne and Silverman, Jeffrey A and Barthel, Ben and DuVall, Michael and Madden, Molly and MacDougall, James and Kilburn, Nicole Rempel and Bronson, Abby and Evanchik, Marc and Gordon, Gilad and Koch, Kevin and Russell, Alan J},
title = {A Phase 1, Double‐Blind, Placebo‐Controlled Trial of Sevasemten ( EDG ‐5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular Dystrophy},
journal = {Muscle & Nerve},
year = {2025},
volume = {72},
number = {3},
pages = {399--407},
doi = {10.1002/mus.28444}
}
EUVIMED